Trial · NCT02469857
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients Achieving Necrotizing Infections Clinical Composite Endpoint (NICCE) | Reltecimod (AB103) 0.5 mg/kg | mITT Population | 69 | Participants | |
| Number of Patients Achieving Necrotizing Infections Clinical Composite Endpoint (NICCE) | Placebo | mITT Population | 59 | Participants | |
| Number of Patients Achieving Necrotizing Infections Clinical Composite Endpoint (NICCE) | Reltecimod (AB103) 0.5 mg/kg | US-mITT Population | 67 | Participants | |
| Number of Patients Achieving Necrotizing Infections Clinical Composite Endpoint (NICCE) | Placebo | US-mITT Population | 50 | Participants | |
| Number of Patients With One or More Adverse Events (AEs) | AB103 0.5 mg/kg | 104 | Participants | ||
| Number of Patients With One or More Adverse Events (AEs) | Placebo | 96 | Participants | ||
| Number of Patients With One or More Serious Adverse Events (SAEs) | AB103 0.5 mg/kg | 44 | Participants | ||
| Number of Patients With One or More Serious Adverse Events (SAEs) | Placebo | 40 | Participants | ||
| Number of Patients With One or More Secondary Infections | AB103 0.5 mg/kg | 30 | Participants | ||
| Number of Patients With One or More Secondary Infections | Placebo | 32 | Participants | ||
| Number of Patients Achieving Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Score of 0 or 1 | Reltecimod (AB103) 0.5 mg/kg | 87 | Participants | ||
| Number of Patients Achieving Day 14 Modified Sequential Organ Failure Assessment (mSOFA) Score of 0 or 1 | Placebo | 74 | Participants | ||
| Intensive Care Unit (ICU)-Free Days | Reltecimod (AB103) 0.5 mg/kg | 20.0 | Full Range 0 to 28 | days | |
| Intensive Care Unit (ICU)-Free Days | Placebo | 18.0 | Full Range 0 to 28 | days | |
| Ventilator-free Days | Reltecimod (AB103) 0.5 mg/kg | 22.0 | Full Range 0 to 28 | days | |
| Ventilator-free Days | Placebo | 21.0 | Full Range 0 to 28 | days | |
| Vasopressor-free Days | Reltecimod (AB103) 0.5 mg/kg | 25.0 | Full Range 0 to 28 | days | |
| Vasopressor-free Days | Placebo | 25.0 | Full Range 0 to 28 | days | |
| Hospital Days | Reltecimod (AB103) 0.5 mg/kg | 18.0 | Full Range 1 to 103 | days | |
| Hospital Days | Placebo | 19.5 | Full Range 2 to 135 | days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02469857/results